BioMark Diagnostics Inc
Research BioMark Diagnostics Inc (20B) on Bullrun: market cap EUR 33.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker20B
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 33.42M
- Financial periodQ1 2026
- RevenueCAD 7.01K
- Net income-CAD 199.47K
- Free cash flowCAD 504.22K
Valuation Snapshot
latest market cap is EUR 33.42M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 91.77K | -CAD 1.70M | -CAD 2.05M | n/a | n/a | CAD 487.70K | CAD 711.78K | CAD 508.03K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 33.42M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About BioMark Diagnostics Inc
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioMark Diagnostics Inc's market cap?
BioMark Diagnostics Inc's market capitalization is EUR 33.42M.
What does BioMark Diagnostics Inc do?
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.